NCT05111821

Iron Chelation in the Prevention of Secondary Degeneration After Stroke

Long-term Iron Chelation in the Prevention of Secondary Remote Degeneration After Stroke

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: University Hospital, Bordeaux · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Stroke is a major cause of disability over the world. While acute therapies have made huge progresses, the number of survivors leaving with clinical consequences of stroke is increasing. Beyond stroke itself, secondary neurodegeneration of disconnected areas, especially of central hubs such as the substantia nigra or the thalamus, could significantly impact the overall outcome of the patients. Data have identified iron accumulation within the disconnected areas as potentially accelerating neurodegeneration. In this research, the main objective is test whether long-term chelation through Deferiprone (Ferrirpox®, Chiesi) administered daily from 3-to-5 days following stroke to 6 months could avoid iron accumulation as measured with Magnetic resonance imaging (MRI) within disconnected areas (substantia nigra). MRI imaging methods such as the quantification of the transverse relaxation rate R2\* provide highly correlated information to the histologically measured iron load

Conditions

• Stroke

Interventions

Type	Name	Description
PROCEDURE	Magnetic Resonance Imaging (MRI)	Quantification of iron will be performed through Magnetic Resonance Imaging
DRUG	Deferiprone treatment	Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d

Timeline

• Start date: 2022-06-08
• Primary completion: 2025-04-17
• Completion: 2025-04-22
• First posted: 2021-11-08
• Last updated: 2025-07-21

Locations

2 sites across 1 country: France